Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program

Cocrystal Pharma, Inc.

Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.
Approximately $500,000 in non-dilutive funding; Phase I award to assess scientific and commercial potential.
Funds will be used to characterize lead candidate molecules inhibiting the influenza polymerase complex.
Successful Phase I completion may qualify Cocrystal to apply for a larger Phase II award.
Company continues to pursue additional non-dilutive government and military funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.